Affiliation:
1. Instituto de Investigacao e Inovacao em Saúde, Universidade do Porto, R. Alfredo Allen, 4200-135, Porto, Portugal
2. Biomedical Sciences Research Complex (BSRC), The North Haugh, The University, St. Andrews,Fife Scotland. KY16 9ST, United Kingdom
Abstract
The trypanosomatids, Trypanosoma brucei, Trypanosoma cruzi and Leishmania
spp, are causative agents of important human diseases such as African sleeping sickness,
Chagas’ disease and Leishmaniasis, respectively. The high impact of these diseases
on human health and economy worldwide, the unsatisfactory available chemotherapeutic
options and the absence of human effective vaccines, strongly justifies the search for new
drugs. The pentose phosphate pathway has been proposed to be a viable strategy to defeat
several infectious diseases, including those from trypanosomatids, as it includes an oxidative
branch, important in the maintenance of cell redox homeostasis, and a non-oxidative
branch in which ribose 5-phosphate and erythrose 4-phosphate, precursors of nucleic acids
and aromatic amino acids, are produced. This review provides an overview of the
available chemotherapeutic options against these diseases and discusses the potential of
genetically validated enzymes from the pentose phosphate pathway of trypanosomatids to
be explored as potential drug targets.
Publisher
Bentham Science Publishers Ltd.
Subject
Pharmacology,Molecular Medicine,Drug Discovery,Biochemistry,Organic Chemistry
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献